Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 57

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2012', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome). 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Interstitial Cystitis (Painful Bladder Syndrome).
- A review of the Interstitial Cystitis (Painful Bladder Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Interstitial Cystitis (Painful Bladder Syndrome) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Interstitial Cystitis (Painful Bladder Syndrome) Therapeutic Products under Development, Key Players in Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics, Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Overview, Interstitial Cystitis (Painful Bladder Syndrome) Pipeline, Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interstitial Cystitis (Painful Bladder Syndrome) Overview
Therapeutics Development
An Overview of Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome)
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Products under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics Development
Astellas Pharma Inc.
Urigen Pharmaceuticals, Inc.
Plethora Solutions Holdings plc
Aquinox Pharmaceuticals Inc.
Rottapharm SpA
Trillium Therapeutics Inc.
Interstitial Cystitis (Painful Bladder Syndrome) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ASP3652 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
URG101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSD597 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TTI-1612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR 3465 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ProtoCure Intravesical Instillation Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heparin + Lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amitriptyline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AQX-1125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LiRIS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omalizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Drug Profile Updates
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Dormant Products
Interstitial Cystitis (Painful Bladder Syndrome) – Product Development Milestones
Featured News & Press Releases
Mar 28, 2012: Trillium Doses First Patient In Phase I Clinical Trial Of TTI-1612 In Interstitial Cystitis
Dec 15, 2011: Trillium To Commence Clinical Testing Of TTI-1612 In Patients With Interstitial Cystitis/Bladder Pain Syndrome
Nov 30, 2011: TARIS Initiates Phase II Clinical Study With LiRIS In Interstitial Cystitis Patients
Jun 30, 2011: Urigen Provides Development Update For URG101
Mar 09, 2011: TARIS Initiates Clinical Study In Interstitial Cystitis Patients
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis
Apr 23, 2010: Urigen Files Request For FDA Meeting
Dec 29, 2008: Urigen Amends Its Core UCSD License For URG101
Aug 20, 2008: Urigen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2012
Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Astellas Pharma Inc., H1 2012
Urigen Pharmaceuticals, Inc., H1 2012
Plethora Solutions Holdings plc, H1 2012
Aquinox Pharmaceuticals Inc., H1 2012
Rottapharm SpA, H1 2012
Trillium Therapeutics Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Drug Profile Updates
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2012
Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
• HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2013
• Down Syndrome – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Interstitial Cystitis Therapy Area Pipeline Report
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013